The company, based in Santa Clara, California, specializes in the development and production of minimally-invasive cardiovascular technology products, including drug-eluting stents, catheters, guidewires, and vena cava filters for the treatment of coronary and peripheral vascular diseases. With a 60-year history of pioneering products, Cordis has built a robust global footprint with operations in over 60 countries. As a standalone company committed to investing $300 million in innovation, Cordis aims to be a $10 billion leader in bringing new technology to the market through bold action at speed, enabling healthcare providers to focus on patient care while reducing costs and enhancing efficiency.